S-1/A: Caring Brands Files S-1/A for NASDAQ Listing & Public Offering

Caring Brands, Inc. filed an S-1/A registration statement for a public offering of 1,000,000 shares and a resale of 2,610,000 shares, contingent on NASDAQ listing, to fund product development and working capital.

Summary

• Caring Brands, Inc. is a wellness consumer products company offering OTC and cosmetic products for hair loss, eczema, psoriasis, vitiligo, and jellyfish sting protection.
• The company is seeking to raise approximately $3,200,000 in net proceeds from a public offering of 1,000,000 shares at an assumed price of $4.00 per share, contingent on NASDAQ listing.
• An additional 2,610,000 shares are registered for resale by selling stockholders, including 2,110,000 warrant shares and 500,000 shares held by Jordan Fried.
• The company has a limited operating history, nominal revenues, and recurring net losses, including $(1,199,353) for the six months ended June 30, 2025, and $(862,791) for the period from April 24 to December 31, 2024.
• Key products include Photocil (for vitiligo and psoriasis), Hair Enzyme Booster (JW-700) (to enhance minoxidil efficacy), CB-101 (for eczema), and NoStingz (sunscreen with jellyfish sting protection).
• Photocil and Hair Enzyme Booster (JW-700) are currently sold in India under a licensing agreement with Cosmofix and San Pellegrino Cosmetics, with Hair Enzyme Booster also available on Amazon in the U.S.
• CB-101 and NoStingz are undergoing reformulation and development, with target U.S. online availability in Q2 2026 for CB-101 and no established timeline for NoStingz.
• The company has secured licensing agreements for Hair Enzyme Booster (JW-700) with Taisho Pharmaceutical Co. in Japan (up to $200,000 in milestone payments and 3% royalty) and with Cosmofix/San Pellegrino for India and 31 other territories (3% royalty, minimum $50,000 annual royalty after first year).
• Caring Brands was separated from Safety Shot Inc. on September 24, 2024, with Safety Shot retaining approximately 18.2% ownership of Caring Brands' common stock.
• The company has a working capital deficiency and its ability to continue as a going concern is in doubt, relying on this offering and future financing.
• Management plans to allocate offering proceeds to product development ($1,900,000), legal & compliance ($100,000), related party loan repayment ($75,000), general & administrative expenses ($250,000), and general working capital ($875,000).

Sentiment

Score: 3

Explanation: The sentiment is low due to significant financial losses, nominal revenues, and a 'going concern' warning from auditors. While there are promising products and market opportunities, the company's current financial state, limited operating history, and past failures in U.S. market penetration for key products present substantial risks. The capital raise is critical for survival and future development, but the underlying financial performance is weak.

Positives

• The company has a diverse pipeline of wellness consumer products addressing significant market opportunities in hair loss, eczema, psoriasis, vitiligo, and sun protection.
• Hair Enzyme Booster (JW-700) has 2 granted and 5 pending patents, and clinical studies show it increases sulfotransferase enzymes needed for minoxidil to work, with a 75% response rate in one trial.
• Photocil has demonstrated significant efficacy in clinical trials for vitiligo and psoriasis, with one study showing 28% achieved 70% re-pigmentation for vitiligo and another showing 43% achieved complete clearance for psoriasis.
• Licensing agreements are in place with Taisho Pharmaceutical Co. for Hair Enzyme Booster in Japan (expected commercial launch in 2025) and with Cosmofix/San Pellegrino Cosmetics for Photocil and Hair Enzyme Booster in India and 31 other territories.
• The global psoriasis treatment market was valued at ~$34 billion in 2023, projected to reach $54-67 billion by 2030, and the global vitiligo treatment market was ~$538.90 million in 2024, projected to reach ~$807.70 million by 2034.
• The global phototherapy treatment market is projected to grow from ~$1.9 billion in 2023 to ~$3.23 billion by 2033, with India's market expanding at an estimated CAGR of 7.8%.
• CB-101 for eczema has 4 pending patents, and the global eczema treatment market was valued at $14 billion in 2022, with 86% of 31.6 million American eczema sufferers dissatisfied with current treatments.
• The company is applying to list its common stock on The Nasdaq Capital Market (NASDAQ) under the symbol CABR, which could enhance market visibility and liquidity.
• The company's manufacturers, Stella Industries Ltd. (India) and DCR Labs (Florida), are compliant with FDA CGMP regulations and ISO-9001 certified, ensuring product quality and stability.

Negatives

• The company has a limited operating history as a standalone public company, making it difficult to accurately evaluate business prospects.
• Caring Brands has incurred recurring losses from operations, generated negative cash flows, and has an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• Revenues were nominal for the six months ended June 30, 2025 ($3,056) and for the period from April 24 to December 31, 2024 ($465), and a net loss of $(1,199,353) and $(862,791) respectively.
• Photocil was removed from the U.S. market in February 2023 due to insufficient sales resulting from a lack of a dedicated sales and marketing team.
• Hair Enzyme Booster (JW-700) sales have been minimal during its initial soft launch period in the U.S. (Q4 2024) as marketing strategies are being refined.
• CB-101 development was on hold pending reformulation, which is expected to resume in Q4 2025/Q1 2026, delaying its U.S. launch to Q2 2026.
• NoStingz was removed from the U.S. market in September 2023 due to insufficient sales and is undergoing reformulation with no established commercial launch timeline.
• The company may not have adequate capital to fund its business and cannot assure that additional financing will be available on acceptable terms or at all, which could lead to curtailment or cessation of operations.
• The company faces intense competition from larger, better-resourced companies in the skin care and hair growth product markets.
• The separation from Safety Shot Inc. may result in the loss of certain benefits (operating diversity, size, borrowing leverage) and increased costs associated with being a standalone public company.
• The company's management has limited experience in managing the day-to-day operations of a public company, potentially leading to additional expenses and distractions.
• The issuance of additional common or preferred stock in the future may cause dilution to existing stockholders.
• The company does not intend to pay dividends for the foreseeable future.

Risks

• Inability to achieve expected benefits from the separation from Safety Shot Inc.
• Limited operating history as a publicly traded company, making historical financial information not necessarily representative of future results.
• Conflicts of interest due to some directors and executive officers owning Safety Shot common stock or holding positions with Safety Shot.
• Inability to develop functional and scalable products and services, or products not being economical to market.
• Competitors holding proprietary rights that preclude marketing or offering superior/equivalent products.
• Inability to upgrade and enhance technologies and products to accommodate new features and expanded service offerings.
• Failure to receive necessary regulatory clearances for products.
• Inability to establish brand name recognition and competitive advantages for products.
• Difficulty in accurately forecasting future revenues due to new business and undeveloped market.
• Inability to adjust spending in a timely manner to compensate for unanticipated revenue reductions.
• Financial situation creating doubt about the ability to continue as a going concern.
• Inability to keep up with rapid technological changes, leading to product obsolescence.
• Inadequate capital to fund the business, potentially leading to curtailment or cessation of operations.
• Inability to successfully compete against companies with substantially greater resources.
• Product liability and related risks exposing the company to significant insurance and loss expenses.
• Inability to develop and maintain brand and reputation for product offerings.
• Failure to develop and introduce new products in a timely and cost-effective manner.
• Adverse publicity associated with products or ingredients, or those of similar companies, affecting sales and revenue.
• Lack of FDA approval for treatment of disease for current products, and potential delays/difficulties in obtaining future regulatory approvals.
• Identification of serious adverse or undesirable side effects during product development.
• Delays or difficulties in enrolling subjects in clinical trials.
• Inability of the company or its licensees/suppliers to manufacture products in sufficient quantities or at defined quality specifications.
• Inability to obtain regulatory approvals for manufacturing facilities.
• Inadequacy of product liability insurance or its future affordability/availability.
• Market opportunities for current and future drug candidates being smaller than believed.
• Inability to establish relationships with licensees or collaborators for sales, marketing, and distribution functions.
• FDA disagreement with product classifications (cosmetic/OTC) requiring reformulation, pre-market approval, or leading to enforcement action.
• Lack of market acceptance by physicians, payers, and patients for OTC/Cosmetic product candidates.
• Subject to federal and state fraud and abuse laws if FDA approval for product candidates is obtained, increasing operating costs and compliance complexity.
• Natural disasters and other events beyond control adversely affecting operations.
• Failure to meet product development and commercialization milestones.
• Disruptions to manufacturing operations due to various factors.
• Inherent risks in international market operations, including macroeconomic conditions, foreign currency exchange rates, political unrest, and regulatory changes.
• Dilution to existing stockholders from raising additional capital through equity or convertible debt securities.
• Restrictive covenants from debt financings impacting business operations.
• Significant strain on resources and demands on management from rapid growth and entry into new markets.
• Changes in tax laws and unanticipated tax liabilities adversely affecting effective income tax rate and profitability.
• Substantial costs from litigation or other proceedings relating to patent and other intellectual property rights.
• Inability to adequately protect intellectual property, leading to reduced product value and inability to compete effectively.
• Dependence on unpublished know-how held by key individuals.
• Expiration of intellectual property protection.
• Reduced disclosure requirements as an emerging growth company making common stock less attractive to investors.
• Strain on resources and management distraction from being a public company.
• Limited experience of management in day-to-day operations of a public company, leading to additional expenses.
• Compliance with changing corporate governance regulations and public disclosures resulting in additional risks and exposures.
• Significant percentage of voting securities held by officers, directors, and significant stockholders, potentially reducing minority stockholder influence.
• Inaccurate or unfavorable research by securities or industry analysts causing stock price decline.
• Issuance of additional common stock or preferred stock causing common stock price to decline.
• Common stock becoming subject to SEC's penny stock rules, affecting trading activity.
• Inability to implement and maintain effective internal control over financial reporting.
• Concurrent resale and potential dilution of stockholders' ownership from selling stockholders.
• Uncertainty of an active, liquid, and orderly trading market for common stock.
• Public offering price not indicative of prevailing trading market prices, which may be volatile.
• Inability to satisfy NASDAQ listing requirements or obtain/maintain listing.

Future Outlook

Caring Brands plans to relaunch Photocil in the U.S. in 2026 and complete reformulation and launch CB-101 for eczema in Q2 2026. The Hair Enzyme Booster (JW-700) is expected to have a full marketing campaign rollout between Q4 2025 and Q1 2026, with Taisho Pharmaceutical Co. launching it commercially in Japan in 2025. NoStingz reformulation and stability testing are expected to resume in Q4 2025, with production initiated between Q4 2025 and Q1 2026, but no commercial launch timeline is established. The company intends to expand its sales and marketing team and explore additional distribution channels, while also seeking acquisition opportunities in the branded consumer products space. The execution of these plans is contingent upon the successful completion of the public offering and obtaining necessary regulatory approvals.

Management Comments

• Management believes that phototherapy treatments, used for conditions such as psoriasis and vitiligo, are set for substantial growth globally.
• Management believes that Psoriasis treatment with Photocil may only address a very small fraction of the market in the US and India.
• Management believes India presents a potential opportunity for market expansion for vitiligo treatments.
• Management believes that Vitiligo treatment with Photocil is expected to address only a very small fraction of the total global market.
• Management believes that its market, industry and economic data is accurate and that its estimates and assumptions are reasonable, but there can be no assurance as to the accuracy or completeness thereof.
• Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

Industry Context

Caring Brands operates in the highly competitive wellness consumer products industry, specifically targeting the over-the-counter (OTC) and cosmetic segments for skin and hair conditions. The company's strategy focuses on clinically validated products with unique mechanisms of action, aiming to differentiate itself from larger, more established competitors. The markets for phototherapy, psoriasis, vitiligo, eczema, and minoxidil are projected to experience significant growth globally, driven by increasing prevalence of skin disorders and demand for effective treatments. However, the industry is characterized by rapid technological change, intense competition, and stringent regulatory requirements, particularly from the FDA and international bodies. The company's reliance on third-party manufacturing and licensing agreements is a common strategy in this sector, but its limited operating history and financial resources pose challenges compared to industry leaders.

Comparison to Industry Standards

• Photocil's narrow-band UV filter technology is noted as proprietary and not found in other sunscreens, differentiating it from conventional UV blockers.
• Photocil's clinical efficacy for vitiligo and psoriasis is compared favorably to conventional phototherapy lamp treatment, which requires frequent physician visits, by offering a topical home-use solution.
• Photocil's topical treatment is presented as more convenient and having fewer side effects than other vitiligo treatments like topical corticosteroids, tacrolimus, and JAK inhibitors (e.g., Ruxolitinib/Opzelura).
• Hair Enzyme Booster (JW-700) is positioned to improve the efficacy of minoxidil, an FDA-approved treatment, distinguishing it from many non-FDA approved nutritional supplements in the hair growth market.
• The company's licensing agreement with Taisho, Japan's leading seller of minoxidil products with $2.6 billion revenue, suggests industry validation of the Hair Enzyme Booster's potential.
• CB-101's prior formulation (JW-100) showed potential superiority to existing prescription drugs for eczema, with 50% of subjects achieving clear or almost clear status with a two-grade improvement compared to 15% in the placebo group (p=0.028).
• The company's products are tested for quality and stability, with manufacturers like Stella Industries Ltd. being ISO-9001 certified and compliant with FDA CGMP regulations (21 CFR 210/211) for OTC drug products, aligning with high industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceeding, nor is its property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of its business.
• None of the directors, officers or affiliates are involved in a proceeding adverse to the business or have a material interest adverse to the business.

Related Party Transactions

• Caring Brands (Nevada) acquired 100% equity in Caring Brands (Florida) from Safety Shot Inc. on September 24, 2024, as part of a separation and exchange agreement. Safety Shot waived an outstanding balance of $275,876 owed by Caring Brands (Florida) as part of this transaction.
• Safety Shot Inc. owns 2,500,000 shares of Caring Brands' common stock, representing approximately 18.2% of outstanding shares.
• On June 20, 2024, Caring Brands entered into a Research Collaboration and Non-Exclusive License Agreement with NOVODX Corporation, a related party (Nancy Torres, a former director of Caring Brands, is CEO of NOVODX). In consideration, Caring Brands issued 3,000,000 shares of restricted common stock to NOVODX.
• In May 2024, NOVODX Corporation participated in Caring Brands' private placement, acquiring 500,000 shares for $500,000 cash, representing approximately 4% equity ownership.
• In June 2024, Caring Brands invested $500,000 in NOVODX's private placement, purchasing 25,134 shares (less than 1% ownership).
• On June 5, 2025, Caring Brands entered into a short-term loan agreement for $50,000 with its CEO, Dr. Glynn Wilson, due November 5, 2025, at an 8% interest rate.
• On July 24, 2025, Caring Brands entered into a short-term loan agreement for $25,000 with its Chairman of the Board, Mr. Brian John, due December 24, 2025, at an 8% interest rate.
• On August 6, 2025, Caring Brands entered into a convertible promissory note for $200,000 with Greentree Financial Group, Inc., which also received 25,000 shares of common stock and 200,000 warrants. Greentree Financial Group, Inc. also received 200,000 shares of common stock for services on September 5, 2025.
• Tyler Moore, the new CFO, had a previous consulting agreement (July 15, 2025) that included 100,000 stock options, which was terminated on September 4, 2025, concurrent with his employment agreement. His employment agreement includes 200,000 restricted shares of common stock as equity compensation.

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience significant dilution from the public offering and potential resale of shares by selling stockholders. The 'going concern' warning indicates a high risk of losing their entire investment if additional capital is not secured. The NASDAQ listing, if successful, could improve liquidity and potentially increase share price, but there is no guarantee.
• **Employees:** The company has four full-time employees, including key executives. The Equity Incentive Plan aims to incentivize employees, but the company's financial instability could impact job security and future compensation.
• **Customers:** The company's ability to develop, manufacture, and market its products, including planned relaunches and new product introductions, directly impacts product availability and customer satisfaction. Past product removals due to insufficient sales suggest challenges in reaching customers effectively.
• **Suppliers/Manufacturers:** The company relies on third-party manufacturers (e.g., Stella Industries Ltd., DCR Labs) and raw material suppliers. Supply chain disruptions or financial instability of Caring Brands could impact these relationships.
• **Creditors:** Related party loans and a convertible promissory note indicate existing debt obligations. The 'going concern' risk poses a threat to the company's ability to repay these debts.

Next Steps

• Complete the public offering of 1,000,000 shares of common stock.
• Secure NASDAQ listing for common stock under the symbol CABR.
• Relaunch Photocil in the United States, targeted for 2026, exploring manufacturing and marketing options.
• Initiate preparation for scaling-up Photocil manufacturing between Q3 and Q4 2025.
• Initiate the FDA registration process for Photocil by Q4 2025.
• Develop a marketing campaign, U.S. market relaunch, and e-commerce platform integration for Photocil between Q4 2025 and Q1 2026.
• Set up manufacturing and develop initial marketing materials for Hair Enzyme Booster (JW-700) by Q1 2026.
• Roll out a full marketing campaign for Hair Enzyme Booster (JW-700) and expand to additional e-commerce platforms, and develop a retail distribution strategy between Q4 2025 and Q1 2026.
• Taisho Pharmaceutical Co. expects to launch Hair Enzyme Booster commercially in Japan in 2025.
• Initiate reformulation process for CB-101 in Q4 2025 and complete it by Q1 2026.
• Initiate production run and clinical testing for CB-101 by Q2 2026.
• Develop marketing materials campaign, U.S. market relaunch, and e-commerce platform integration for CB-101 by Q3 2026, with a target launch date of Q2 2026.
• Complete reformulation and initiate stability testing for NoStingz by Q4 2025.
• Complete NoStingz stability testing and initiate FDA registration process by Q1 2026.
• Initiate the production run and finalize the launch timeline for NoStingz between Q4 2025 and Q1 2026.
• Evaluate market opportunities for the Ebola Rapid Test License.
• Expand sales and marketing team and pursue additional distribution channels, focusing on strengthening e-commerce presence before traditional retail.
• Seek acquisition opportunities in the branded consumer products space, including additional OTC/cosmetic therapeutic and skin care brands.
• Continually update and expand the corporate website (caringbrands.com) and refine online retail strategies.

Key Dates

Recommendation

The company presents a highly speculative investment with significant risks. It has a limited operating history, nominal revenues, and substantial recurring net losses, leading to a 'going concern' warning from its auditors. While the company has a pipeline of potentially promising products and strategic licensing agreements, its past failures in U.S. market penetration for key products (Photocil, NoStingz) due to inadequate sales and marketing, coupled with delays in new product development (CB-101), raise serious concerns about its commercial viability. The proposed public offering and NASDAQ listing are critical for survival, but the immediate dilution for new investors is substantial ($3.77 per share on a $4.00 offering price), and there's no assurance of a sustained active trading market or successful execution of its business plan. The heavy reliance on future capital raises and the high degree of competition in its target markets further exacerbate the risk profile. Given the severe financial distress and operational uncertainties, a seasoned investor would likely view this as a 'sell' or 'avoid' situation due to the high probability of capital loss.

Keywords

Wellness Consumer Products, OTC Products, Cosmetic Products, Hair Loss Treatment, Eczema Treatment, Psoriasis Treatment, Vitiligo Solution, Jellyfish Sting Protection, Photocil, Hair Enzyme Booster, CB-101, NoStingz, Minoxidil, FDA Registration, NASDAQ Listing, Public Offering, SEC Filing, S-1/A, Biopharmaceutical, Dermatology, Intellectual Property, Clinical Trials, Capital Raise, Related Party Transactions, Going Concern